Livelli di DNA tumorale circolante come marcatore predittivo per il passaggio precoce al trattamento per i pazienti con carcinoma mammario metastatico (stadio IV)
Livelli di DNA tumorale circolante come marker predittivo per il passaggio precoce al trattamento per i pazienti con carcinoma mammario metastatico (stadio IV): uno studio di fase 2 randomizzato in aperto
The majority of patients (pts) with breast cancer have hormone receptor positive (HR+) disease, and this holds true for pts with advanced breast cancer (ABC). Currently frontline therapy for pts with HR+ ABC is antihormonal therapy with an aromatase inhibitor or selective estrogen receptor degrader plus a CDK4/6i. The proposed trial is a randomized study to further evaluate the potential benefit of switching a frontline regimen at the time that a molecular signal, ctDNA, suggests progression prior to detection of clinical progression using standard methods. The purpose of this study is to determine whether switching treatment earlier in the disease process, based on molecular progression, will increase the amount of time that a patient's metastatic breast cancer is controlled compared to patients with metastatic breast cancer who receive treatment later based on diagnostic imaging results or other methods currently used in medical practice.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
- Droga: AI+CDK4/6i
- Droga: SERD+CDK4/6i
- Droga: mTOR inhibitor + AI
- Droga: mTOR inhibitor + SERD
- Droga: mTOR inhibitor + Selective estrogen receptor modulator
- Droga: PI3K inhibitor + SERD
- Droga: PI3K inhibitor + AI
- Droga: Chemotherapy
- Droga: Oral SERD
- Droga: PARPi
- Droga: AKT inhibitor
- Altro: Step 3 Arm 2
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Florida
-
Miami, Florida, Stati Uniti, 33136
- University of Miami
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Men or women age ≥ 18 years.
-
Patients with a diagnosis of ER+, human epidermal growth factor receptor 2 negative (HER2-) metastatic (Stage IV) breast cancer. Positivity status is defined as >10% staining for ER and immunohistochemistry (IHC) 0+ or IHC 1 or 2+ staining for HER-2, and fluorescence in situ hybridization (FISH) negative with standard pathology staining methods.
-
Patients with de novo metastatic disease at the Screening Visit must undergo a SOC diagnostic biopsy.
-
Archived tumor tissue available.
-
Women and men with proven locally advanced, locoregionally recurrent or metastatic disease adenocarcinoma of the breast not amenable to curative therapy. Note: patients relapsing while on adjuvant tamoxifen or AI are eligible for this study.
-
No prior systemic anticancer therapy for metastatic or advanced disease (chemotherapy targeted therapy or endocrine therapy (ET)).
Note 1: prior endocrine therapy in the metastatic setting is not allowed unless initiated <30 days from study initiation or Cycle 1, Day 1 (C1D1).
Note 2: prior initiation of luteinizing hormone-releasing hormone (LHRH) agonist or bone-directed agents, however, is allowed.
-
No visceral crisis. Visceral crisis is defined as advanced, symptomatic, visceral spread that is at risk of life-threatening complication in the short term and that requires chemotherapy.
-
Adequate organ and marrow function as defined below:
-
Hematological
- Absolute neutrophil count (ANC) ≥1,500 cells/mm³
- Platelets ≥100,000 cells/mm³
- Hemoglobin ≥9.0 g/dL or ≥8.0 g/dL for patients with bone metastases and/or menstruating females with evidence of iron deficiency
-
Renal
- Serum creatinine or Measured or calculated creatinine clearance (glomerular filtration rate (GFR) can also be used in place of creatinine or creatinine clearance (CrCl)) ≤ 1.5 x upper limit of normal (ULN) or CrCl ≥ 40 mL/min. CrCl should be calculated per institutional standard.
-
Hepatic
- Serum total bilirubin < 1.0 ULN
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase (SGOT)) and alanine transaminase (ALT) (serum glutamic-pyruvic transaminase (SGPT)). Aminotransferase (AST and ALT) ≤ 2.5 x ULN or 5 X ULN for patients with liver metastases
- Albumin ≥ 2.5 mg/dL
-
-
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST V.1.1) or non-measurable disease that is evaluable.
-
Patients with an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1.
-
Ability to understand and the willingness to sign a written informed consent document.
-
Life expectancy >3 months.
-
Postmenopausal women, women with suppressed ovarian function, or premenopausal women, provided they are being treated with monthly LHRH analogues and are willing to continue to receive LHRH agonist therapy for the duration of the trial. Menopausal patients or patients with suppressed ovarian function are defined as follows:
-
Women with bilateral oophorectomy
-
Postmenopausal women, as defined by any of the following criteria:
- Age 60 or over
- Age 50-59 years and meets the following criterion:
- Amenorrhea for ≥12 months and follicle-stimulating hormone and estradiol levels within the postmenopausal range
- Women with hysterectomy or chemotherapy-induced amenorrhea. Note: Patients with hysterectomy or chemotherapy-induced amenorrhea must display follicle stimulating hormone and estradiol levels within the postmenopausal range.
-
-
Resolution of all acute toxic effects from prior anticancer therapy or surgical procedures as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) V 5.0 to grade 1 (except alopecia or other toxicities not considered a safety risk for the patient at Investigator's discretion)
Exclusion Criteria:
- Patients who are currently receiving or have received treatment for a secondary cancer other than resected non-melanoma skin cancer lesions or in situ cancer within the past 24 months.
- Prior exposure to CDK4/6i ≤12 months prior to enrollment.
- Use of investigational drugs ≤28 days prior to study enrollment and during the study.
- History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or that makes participation in the trial to be not in the best interest of the patient in the opinion of the Investigator.
- Locally advanced breast cancer or locoregional relapse amenable for any treatment with curative intent.
- HER2+ or equivocal tumor status either on the primary or on the recurrent tumor defined as IHC 3+, FISH/chromogenic in situ hybridization (CISH) amplified or FISH/CISH equivocal according to the American Society of Clinical Oncologists (ASCO) 2015 criteria.
- Prior endocrine therapy in the metastatic setting is not allowed unless initiated < 30 days from study initiation or Cycle 1, Day 1 (C1D1).
- Prior treatment with any CDK 4/6 inhibitor in the metastatic setting is not allowed.
- Any major surgery (defined as requiring general anesthesia) or significant traumatic injury within 4 weeks of treatment; however, surgical diagnostic procedure is allowed (even if under general anesthesia).
- Known active, bleeding diathesis.
- Any serious known concomitant systemic disorder incompatible with the study (at the discretion of the Investigator).
- Patients unable to swallow tablets.
- History of malabsorption syndrome or other condition that would interfere with enteral absorption.
- Known active uncontrolled or symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms, cerebral edema and/or progressive growth. Patients with a history of CNS metastases or cord compression are eligible if they have been definitively treated with local therapy (e.g., radiotherapy, stereotactic surgery) and are clinically stable and off anticonvulsants and steroids for at least 4 weeks before treatment initiation.
- Known hypersensitivity to letrozole, anastrozole, exemestane, fulvestrant, or CDK4/6i or any of their excipients.
- Uncontrolled electrolyte disorders that can compound the effects of a corrected QT (QTc) interval prolonging drug (eg, hypocalcemia, hypokalemia, hypomagnesaemia).
- Patients treated within the last 7 days prior to treatment start in the study with medications that are known to be cytochrome (CYP) CYP3A4 inhibitors or drugs that are known to be CYP3A4 inducers.
- Patients requiring palliative radiation within the 30 days following C1D1 in Step 1.
- Patients already included in another therapeutic trial evaluating an investigational medicinal product or having received an investigational medicinal product within 3 months.
- Any stage II, III, or IV cancer within 5 years preceding patient enrollment in the trial; however, multiple breast cancers (contralateral/ipsilateral cancers/local relapses) are allowed pending all tumor masses were ER+.
- Any history of hematologic malignancy.
- Pregnancy or lactation period. Women of childbearing potential must implement adequate nonhormonal contraceptive measures (barrier methods, intrauterine contraceptive devices, sterilization; LHRH agonist cannot be considered as an efficient contraceptive measure) during study treatment and for 90 days after discontinuation. A serum pregnancy test must be negative in premenopausal women or women with amenorrhea of less than 12 months.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Step 2 Arm 1: No Modification of Therapy
Participants in Step 2 Arm 1 will first undergo ctDNA monitoring in Step 1, providing blood samples for ctDNA testing at the following timepoints until a rise in ctDNA leading to a ratio (ctDNA result at time of assessment/ctDNA level at baseline) greater than (>) 1 occurs:
Participants will have no change in standard of care therapy administered in Step 1. |
Participants will receive standard of care one of three available AI therapies in combination with one of three available CDK4/6i therapies:
Altri nomi:
Participants will receive standard of care SERD therapy in the form of Fulvestrant, in combination with one of three one of three available CDK4/6i therapies:
Altri nomi:
|
|
Sperimentale: Step 2 Arm 2: Early Switch in Therapy
Participants in Step 2 Arm 2 undergo an early switch in standard of care therapy received in Step 1:
Participants will receive this therapy for approximately 14 months. |
Participants will receive standard of care one of three available AI therapies in combination with one of three available CDK4/6i therapies:
Altri nomi:
Participants will receive standard of care SERD therapy in the form of Fulvestrant, in combination with one of three one of three available CDK4/6i therapies:
Altri nomi:
Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with AI therapy (Exemestane) in Step 2 Arm 2 and Step 3. mTOR inhibitor + AI therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Altri nomi:
Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with SERD therapy (Fulvestrant), in Step 2 Arm 2 and Step 3. mTOR inhibitor + SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Altri nomi:
Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with selective estrogen receptor modulator therapy (Tamoxifen) in Step 2 Arm 2 and Step 3. mTOR inhibitor + Selective estrogen receptor modulator therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Altri nomi:
Participants will receive standard of care one PI3K inhibitor therapy (Alpelisib), in combination with SERD therapy (Fulvestrant) in Step 2 Arm 2 and Step 3. PI3K inhibitor + SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Altri nomi:
Participants will receive standard of care a PI3K inhibitor therapy (Alpelisib), in combination with an AI therapy (Letrozole) in Step 2 Arm 2 and Step 3. PI3K inhibitor + AI therapy administered as one of the available options for early switch from SERD+CDk4/6i therapy in administered in Step 1.
Altri nomi:
Chemotherapy administered standard of care as an alternative therapy in Step 2 Arm 2 and Step 3.
Altri nomi:
Participants will receive standard of care oral SERD therapy (Elacestrant) in Step 2 Arm 2 and Step 3. Oral SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Altri nomi:
For participants with germline breast cancer gene (BRCA) mutation(s). Participants will receive standard of care PARPi (Olaparib or Talazoparib) therapy in Step 2 and Step 3.
Altri nomi:
For participants with tumors with one or more phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) or AKT serine/threonine kinase 1 (AKT1) or phosphatase and tensin homolog (PTEN) alterations. Participants in Step 2 and Step 3 will receive standard of care AKT inhibitor as an alternative therapy.
Altri nomi:
|
|
Sperimentale: Step 3: Treatment for Patients in Arm 1
For participants who were randomized to Step 2 Arm 1 and experience first clinical progression. Participants will receive second-line treatment, having the option to change from their AI+CDK4/6i to SERD+CDK4/6i, or from SERD+CDK4/6i treatment to alternative endocrine therapy or chemotherapy. Therapy options for Step 3 are the same as listed for participants randomized to Step 2 Arm 2 and is administered standard of care. Participants will receive this therapy for approximately 6 months. |
Participants will receive standard of care one of three available AI therapies in combination with one of three available CDK4/6i therapies:
Altri nomi:
Participants will receive standard of care SERD therapy in the form of Fulvestrant, in combination with one of three one of three available CDK4/6i therapies:
Altri nomi:
Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with AI therapy (Exemestane) in Step 2 Arm 2 and Step 3. mTOR inhibitor + AI therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Altri nomi:
Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with SERD therapy (Fulvestrant), in Step 2 Arm 2 and Step 3. mTOR inhibitor + SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Altri nomi:
Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with selective estrogen receptor modulator therapy (Tamoxifen) in Step 2 Arm 2 and Step 3. mTOR inhibitor + Selective estrogen receptor modulator therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Altri nomi:
Participants will receive standard of care one PI3K inhibitor therapy (Alpelisib), in combination with SERD therapy (Fulvestrant) in Step 2 Arm 2 and Step 3. PI3K inhibitor + SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Altri nomi:
Participants will receive standard of care a PI3K inhibitor therapy (Alpelisib), in combination with an AI therapy (Letrozole) in Step 2 Arm 2 and Step 3. PI3K inhibitor + AI therapy administered as one of the available options for early switch from SERD+CDk4/6i therapy in administered in Step 1.
Altri nomi:
Chemotherapy administered standard of care as an alternative therapy in Step 2 Arm 2 and Step 3.
Altri nomi:
Participants will receive standard of care oral SERD therapy (Elacestrant) in Step 2 Arm 2 and Step 3. Oral SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Altri nomi:
For participants with germline breast cancer gene (BRCA) mutation(s). Participants will receive standard of care PARPi (Olaparib or Talazoparib) therapy in Step 2 and Step 3.
Altri nomi:
For participants with tumors with one or more phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) or AKT serine/threonine kinase 1 (AKT1) or phosphatase and tensin homolog (PTEN) alterations. Participants in Step 2 and Step 3 will receive standard of care AKT inhibitor as an alternative therapy.
Altri nomi:
|
|
Sperimentale: Step 3: Treatment for Patients in Arm 2
For participants who were randomized to Step 2 Arm 2 and experience first clinical progression. Total participation duration is approximately 6 months. |
Participants will receive third-line treatment standard of care as per their treating physician's choice according to National Comprehensive Cancer Network (NCCN) guidelines. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression-Free Survival 1 (PFS1) Among Participants in Step 2
Lasso di tempo: Up to 36 months
|
PFS1 is defined as the elapsed time in months from the date of randomization (at time a rise in ctDNA ratio > 1 is detected prior to clinical progression) to the date of first clinical progression or death as determined by standard clinical methods or death in randomized participants. |
Up to 36 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of participants in Step 1 with rising ctDNA ratio > 1
Lasso di tempo: Up to 36 months
|
The number of participants with rising circulating tumor DNA (ctDNA) ratio > 1 and no synchronous clinical progression in Step 1 will be reported. |
Up to 36 months
|
|
Percentage of participants in Step 1 with rising ctDNA ratio > 1
Lasso di tempo: Up to 36 months
|
The percentage of participants with rising ctDNA ratio > 1 and no synchronous clinical progression in Step 1 will be reported. |
Up to 36 months
|
|
Time from enrollment to rise in ctDNA ratio > 1 for Participants in Step 1
Lasso di tempo: Up to 36 months
|
The time measured in months from enrollment to rise in ctDNA ratio > 1 in participants in Step1 without synchronous clinical progression will be reported. |
Up to 36 months
|
|
Overall Response Rate (ORR) Among Participants in Step 2
Lasso di tempo: Up to 36 months
|
The overall response rate (ORR) will be defined as the percentage of participants achieving best response of complete response (CR) or partial response (PR) to protocol therapy. Response will be assessed by treating physician using the revised Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1. |
Up to 36 months
|
|
Clinical Benefit Rate (CBR) Among Participants in Step 2
Lasso di tempo: Up to 36 months
|
The clinical benefit rate (CBR) is defined as the percentage of patients with best treatment response of complete response (CR), partial response (PR), or stable disease (SD) will be reported. Response will be assessed by treating physician using the revised Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1. |
Up to 36 months
|
|
Progression-Free Survival 2 (PFS2) Among Participants in Step 3
Lasso di tempo: Up to 36 months
|
PFS in Step 3, which will be called PFS2, and is defined as the elapsed time in months from the date of randomization in Step 2 to date of second clinical progression or death during Step 3. |
Up to 36 months
|
|
Progression-Free Survival 3 (PFS3) Among Participants in Step 3
Lasso di tempo: Up to 36 months
|
PFS in Step 3, which will be called PFS2, and is defined as the elapsed time in months from the date of first clinical progression in Step 2 to date of second clinical progression or death during Step 3. |
Up to 36 months
|
|
Overall Response Rate (ORR) Among Participants in Step 3
Lasso di tempo: Up to 36 months
|
The overall response rate (ORR) will be defined as the percentage of participants in Step 3 achieving best response of complete response (CR) or partial response (PR) to protocol therapy. Response will be assessed by treating physician using the revised Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1. |
Up to 36 months
|
|
Clinical Benefit Rate (CBR) Among Participants in Step 3
Lasso di tempo: Up to 36 months
|
The clinical benefit rate (CBR) is defined as the percentage of patients in Step 3 with best treatment response of complete response (CR), partial response (PR), or stable disease (SD) will be reported. Response will be assessed by treating physician using the revised Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1. |
Up to 36 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Frances Valdes-Albini, MD, University of Miami
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Malattie della pelle
- Malattie del seno
- Malattie della pelle e del tessuto connettivo
- Neoplasie mammarie
- Effetti fisiologici dei farmaci
- Meccanismi molecolari dell'azione farmacologica
- Ormoni
- Ormoni, sostituti ormonali e antagonisti ormonali
- Inibitori enzimatici
- Inibitori della sintesi steroidea
- Antagonisti ormonali
- Antagonisti degli estrogeni
- Modulatori del recettore degli estrogeni
- Aminoacidi, peptidi e proteine
- Proteine
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Terapie
- Azoli
- Acidi nucleici, nucleotidi e nucleosidi
- Azioni farmacologiche
- Azioni e usi chimici
- Idrocarburi
- Idrocarburi, ciclici
- Carboidrati
- Alcaloidi
- Idrocarburi, aromatici
- Composti policiclici
- Glicosidi
- Enzimi
- Enzimi e coenzimi
- Indoli
- Deossictidina
- Citidina
- Nucleosidi di pirimidina
- Pirimidine
- Steroidi
- Composti anelli fusi
- Derivati di benzene
- Nitrili
- Macrolidi
- Lattoni
- Nucleosidi
- Uracile
- Pirimidinoni
- Vinca Alkaloids
- Alcaloidi di triptamina di secologia
- Alcaloidi indolo
- Indolizidine
- Indolizine
- Estradiolo
- Estrene
- Estrane
- Congeneri di estradiolo
- Ormoni steroidi gonadali
- Ormoni gonadali
- Deossiribonucleosidi
- Fluorouracile
- Triazoli
- Stilbenes
- Composti benzilidene
- Ribonucleotidi
- Nucleotidi
- Transferasi
- Proteina serina-treonina chinasi
- Protein chinasi
- Fosfotransferasi (accettatore del gruppo di alcol)
- Fosfotransferasi
- Peptidi e proteine di segnalazione intracellulare
- Proteine del ciclo cellulare
- Proteine del neoplasma
- Poliribonucleotidi
- Polinucleotidi
- Zuccheri di Adenosina Difosfato
- Nucleosidi Difosfato Zuccheri
- Proteine Proto-Oncogene
- Proteine Oncogene
- Chinasi Dipendenti dalle Cicline
- Chinasi Proteiche Dirette da Prolina
- Adenosina Difosfato Ribosio
- Capecitabina
- Letrozolo
- Fulvestrant
- Vinorelbina
- Everolimo
- Anastrozolo
- Sirolimo
- Tamoxifene
- Inibitori dell'aromatasi
- Modulatori selettivi del recettore degli estrogeni
- Abemaciclib
- Terapia farmacologica
- Capivasertib
- taxano
- olaparib
- ribociclib
- Talazoparib
- Palbociclib
- Esemestane
- Elacestrant
- eribulina
- Alpelisib
- Fosfatidilinositolo 3-chinasi
- Proteine proto-oncogene c-akt
- Chinasi 4 Dipendente dalle Cicline
- TOR Serine-Threonine Chinasi
- Poli Adenosina Difosfato Ribosio
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 20221297
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .